婦人科癌に対するPaclitaxel/Carboplatin/Meloxicam併用療法による第2相試験(特別講演III, 第152回名古屋市立大学医学会例会)

概要

論文の詳細を見る
Objectives: We studied to estimate for the response rate and the safety of paclitaxel/carboplatin (TC) with cyclooxygenase-2Inhibitor (meloxicam) as fist-line chemotherapy in gynecologic cancers.Methods: Fifty nine patients of 31 ovarian cancers and 25 endometrial cancers received paclitaxel 175mg/m^2 and carboplatin AUC 6 consecutively on day 1 of a 21 day cycle, for 6 planned cycles. Patients receiced oral meloxicam at 10mg/body diary from the day before the first chemotherapy until day 28 of the sixth cycle. Response rate was assessed according to RECIST criteria, and adverse effect to CTCAE ver3.0.Result: These were 3CRs and 2 PRs among 7 patients evaluated, and the overall response rate was 71.4%. The degree of grade 1-2 neurotoxicity was 37.5%, and grade 3 was 5.4%. Nausea, vomiting, and hematologic toxicities were common.Conclusion: The response rate was as high as without meloxicam. High grade neurotoxicity was relatively rare, and TC with meloxicam therapy could be done in safety. We will observe the progression-free an the overall survival time in the future.
名古屋市立大学の論文
2009-01-30